Vertex Pharmaceuticals (VRTX) Liabilities and Shareholders Equity (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Liabilities and Shareholders Equity of $26.5 billion for Q1 2026, up 15.75% year-over-year from $22.9 billion in Q1 2025, and up 3.28% quarter-over-quarter from $25.6 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $26.5 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 15.75% year-over-year to $26.5 billion; the TTM figure through Mar 2026 stood at $101.0 billion (up 15.08% YoY), while the FY2025 annual figure was $25.6 billion, up 13.8% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $26.5 billion, up from $25.6 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $26.5 billion in Q1 2026, with the low at $14.3 billion in Q1 2022.
- The 5-year median for Liabilities and Shareholders Equity is $22.2 billion (2024), against an average of $21.2 billion.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 35.13% in 2022, then fell 4.34% in 2025.
- Vertex Pharmaceuticals' Liabilities and Shareholders Equity stood at $18.2 billion in 2022, then advanced by 25.23% to $22.7 billion in 2023, then decreased by 0.87% to $22.5 billion in 2024, then gained by 13.8% to $25.6 billion in 2025, then climbed by 3.28% to $26.5 billion in 2026.
- Business Quant data shows VRTX's Liabilities and Shareholders Equity at $26.5 billion in Q1 2026, $25.6 billion in Q4 2025, and $24.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.42 Bn |
| Mar 31, 2026 | 26.48 Bn |
| Dec 31, 2025 | 25.64 Bn |
| Sep 30, 2025 | 24.86 Bn |
| Jun 30, 2025 | 24.04 Bn |
| Mar 31, 2025 | 22.88 Bn |
| Dec 31, 2024 | 22.53 Bn |
| Sep 30, 2024 | 22.24 Bn |
| Jun 30, 2024 | 20.13 Bn |
| Mar 31, 2024 | 23.92 Bn |
| Dec 31, 2023 | 22.73 Bn |
| Sep 30, 2023 | 21.73 Bn |
| Jun 30, 2023 | 20.35 Bn |
| Mar 31, 2023 | 18.97 Bn |
| Dec 31, 2022 | 18.15 Bn |
| Sep 30, 2022 | 16.71 Bn |
| Jun 30, 2022 | 15.58 Bn |
| Mar 31, 2022 | 14.26 Bn |
| Dec 31, 2021 | 13.43 Bn |
| Sep 30, 2021 | 12.62 Bn |